Oellgaard, Jens
Gæde, Peter
Rossing, Peter
Rørth, Rasmus
Køber, Lars
Parving, Hans-Henrik
Pedersen, Oluf
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 14 January 2018
Accepted: 25 April 2018
First Online: 30 May 2018
Duality of interest
: Since completion of the Steno-2 21.2 years follow-up data acquisition, data management and interpretation, JO has been employed by Novo Nordisk Scandinavia A/B, Region Denmark. PR reports having given lectures for Astra Zeneca, Bayer and Boehringer Ingelheim, has served as a consultant for AbbVie, Astra Zeneca, Bayer, Eli Lilly, Boehringer Ingelheim, Astellas, Janssen and Novo Nordisk (all fees given to the Steno Diabetes Center) and has equity interest in Novo Nordisk. HHP has equity interest in Merck and receives honoraria from AbbVie and Novartis. OP has equity interest in Novo Nordisk A/S. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research centre at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation. PG, RR and LK declare that there is no duality of interest associated with this manuscript.